论文部分内容阅读
在经历了几年的战略摇摆期之后,最早进入中国的老牌跨国药企怎样在中国市场提速?一场圆桌会议在上海一间普通会议室里举行,上海市卫生局、医院、医保局等要员应邀出席。会议室中随处可见的百时美施贵宝LOGO,让参会者既熟悉又陌生。这是一家最早进入中国的跨国药企,但在近年来愈加激烈的竞争中却显现疲态。面对百时美施贵宝全球CEOLamberto Andreotti率领的11人高管团队,参会代表们言谈并不客
After a few years of strategic swing, how many veteran multinational pharmaceutical companies entering China are speeding up in the Chinese market? A roundtable was held in an ordinary conference room in Shanghai. Shanghai Municipal Health Bureau, the hospital, the Medicare Bureau, etc. Members are invited to attend. Bristol-Myers 宝 LOGO can be seen everywhere in the conference room, so that participants are both familiar and unfamiliar. This is the first multinational pharmaceutical company to enter China, but has shown signs of weakness in the increasingly fierce competition in recent years. In the face of Bristol-Myers Squibb global CEOLamberto Andreotti, led by 11-member team, the participants did not talk